BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/14/2025 5:49:34 AM | Browse: 12 | Download: 36
 |
Received |
|
2025-05-15 05:55 |
|
Peer-Review Started |
|
2025-05-15 05:56 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-05-20 23:56 |
|
Revised |
|
2025-05-29 02:13 |
|
Second Decision |
|
2025-07-07 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-07-07 07:19 |
|
Articles in Press |
|
2025-07-07 07:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-08-01 07:50 |
|
Publish the Manuscript Online |
|
2025-08-14 05:49 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Cost-effectiveness analysis of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency in China
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hansoo Kim, Joshua Byrnes, Kui-Rong Jiang, Zhuan Liao, Arun Jones, Kyoo Kim, Dafni Fragkogianni and Keith J Roberts |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Arun Jones, Health Economics Group, Griffith University, 1 Parklands Dr, Gold Coast QLD4215, Queensland, Australia. arun.jones@griffith.edu.au |
| Key Words |
Pancreatic exocrine insufficiency; Pancreatic enzyme replacement therapy; Cost-effectiveness analysis; National essential medicine list; China |
| Core Tip |
Pancreatic enzyme replacement therapy (PERT) is a first-line treatment for pancreatic exocrine insufficiency (PEI). In China, PERT is not yet listed on the national essential medicine list, which is often a pre-requisite for patients in China to gain access to life-saving treatments. Chinese health policy has an increased emphasis on cost-effectiveness analysis as a prerequisite for drug reimbursement. This analysis undertakes a cost-effectiveness analysis on PERT for the treatment of PEI from a Chinese societal perspective, finding that PERT is cost-effective for the treatment of PEI in China. |
| Publish Date |
2025-08-14 05:49 |
| Citation |
<p>Kim H, Byrnes J, Jiang KR, Liao Z, Jones A, Kim K, Fragkogianni D, Roberts KJ. Cost-effectiveness analysis of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency in China. <i>World J Gastrointest Oncol</i> 2025; 17(8): 109544</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i8/109544.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i8.109544 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
